Progenics Pharma (PGNX) Says Data Presented at SNMMI Meeting Highlights Potential of its PSMA-Targeted Imaging Agent, PyL, in Detecting Prostate Cancer

June 25, 2019 8:36 AM
Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles